6:16 AM
Nov 30, 2016
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Acute myelogenous leukemia (AML); lymphoma; multiple myeloma (MM)

In vitro and mouse studies identified an MCL1 inhibitor that could help treat AML, lymphoma and MM. NMR-based fragment screening, chemical synthesis and optimization, and in vitro testing yielded a...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >